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Abstract
Background: The number of septic total hip arthroplasty (THA) revisions is increasing continuously, placing a
growing financial burden on hospitals. Orthopedic departments performing septic THA revisions have no basis for
decision making regarding resource allocation as the costs of this procedure for the departments are unknown. It
is widely assumed that septic THA procedures can only be performed at a loss for the department. Therefore, the
purpose of this study was to investigate whether this assumption is true by performing a detailed analysis of the
costs and revenues for two-stage septic THA revision.
Methods: Patients who underwent revision THA for septic loosening in two sessions from January 2009 through
March 2012 were included in this retrospective, consecutive cost study from the orthopedic department’s point
of view. We analyzed variable and case-fixed costs for septic revision THA with special regard to implantation and
explantation stay. By using marginal costing approach we neglected hospital-fixed costs. Outcome measures
include reimbursement and daily contribution margins.
Results: The average direct costs (reimbursement) incurred for septic two-stage revision THA was €10,828 (€24,201).
The difference in cost and contribution margins per day was significant (p < .001 and p = 0.019) for ex- and
implantation (€4147 vs. €6680 and €429 vs. €306) while length of stay and reimbursement were comparable.
Conclusions: This is the first detailed analysis of the hospital department’s cost for septic revision THA performed in
two sessions. Disregarding hospital-fixed costs the included variable and case fixed-costs were covered by
revenues. This study provides cost data, which will be guidance for health care decision makers.
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Background
Currently, one million primary total hip arthroplasties
(THA) are performed worldwide each year [1]. It has
been estimated that this number will double over the
next two decades [1]. Factors contributing to this ex-
pected increase include the demographic trend of a
rapidly aging population and the fact that today’s eld-
erly people are more active than previous generations.
These demographic developments as well as the ten-
dency to perform hip replacement surgery at an in-
creasingly earlier age contribute to a growing number
of individuals with artificial hips. Naturally, also the
number of patients who need a revision THA due to
septic loosening will increase [2–5]. Periprosthetic in-
fection is a devastating complication in patients with
hip prosthesis and is associated with higher mortality,
morbidity, and health care use [1, 2]. For chronic hip in-
fections, two-stage revision is the gold standard [1, 6].
Septic hip revision is a technically complex and time-
consuming procedure and requires more resources than
primary THA [1, 4, 6–8]. The duration of hip revision
* Correspondence: richard.kasch@uni-greifswald.de
1Center of Orthopaedics, Trauma Surgery and Rehabilitation Medicine, Clinic
and Outpatient Clinic for Orthopaedics and Orthopaedic Surgery, University
Medicine Greifswald, Greifswald, Germany
Full list of author information is available at the end of the article
© 2016 Kasch et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kasch et al. BMC Musculoskeletal Disorders  (2016) 17:112 
DOI 10.1186/s12891-016-0962-6
surgery is longer, the prostheses are more expensive, sur-
gical implantation costs are higher, patients stay in hos-
pital longer, and there are more complications [4, 7].
This study was performed in a hospital setting being
reimbursed by diagnosis related groups (DRG), which
follows the fee-per-case approach. In most health care
systems, hospitals are reimbursed on the basis of DRGs
rather than on daily rates. In the past it got more and
more challenging to ensure that at least their costs are
recovered when fulfilling their obligation to treat pa-
tients. Hospitals making a deficit may not survive. Thus,
hospitals and individual departments must analyze their
costs to have a sound basis for decision making. For an
orthopedic department, this means that the relevant
costs of septic THA need to be calculated for proper re-
source allocation and decisions about the service portfolio.
With the exception of a few highly specialized centers,
most hospitals perform a wide spectrum of different pro-
cedures. Ideally, the total revenues accruing to a hospital
from this mix of procedures should be high enough to
cover all liabilities. For a hospital to operate economic-
ally, the reimbursement for complex cases that require
high levels of resources should at least cover the variable
costs per case, while the revenues from other, more
common procedures should pay the hospital’s total fixed
costs [7, 9].
Contribution margin approach
Most international studies published in the literature
that analyze the costs of septic revision THA use a total
cost approach, not separating between fixed and variable
costs [7, 10–13]. The total cost approach does not pro-
vide data on which a hospital department can base fu-
ture decisions [9, 14], while the contribution margin
approach could provide data that can serve as a basis for
decision making. A hospital has variable, fixed case and
hospital-fixed costs. In cost accounting, variable costs
are expenses that increase or decrease in direct relation
to the services or production volume. In the case of a
hospital, variable costs are costs that change with the
number of patients treated (e.g., costs for implants or
medication) [15, 16]. In contrast, the hospital’s fixed
costs are independent of how many patients are treated
(e.g., costs for energy, gardening, administration). Such
fixed costs can only be modified in the long term and
are neglected in the contribution margin approach [17].
Fixed case costs, like variable case costs, are assigned to
the respective department treating the patients. Unlike
variable case costs, fixed case costs are not related to the
treatment of an individual patient but simply arise because
there are patients with that diagnosis (e.g., personnel
costs, operation of an intensive care unit (ICU)). Figure 1
illustrates the marginal costing approach in detail. All
costs are illustrated in orange, while reimbursement and
contribution margins are colored in blue.
Contribution margin I refers to the difference be-
tween net revenues and variable costs. Subtraction of
variable and fixed case costs from overall revenues
yields contribution margin II. If the result is negative,
the orthopedic department incurs a deficit from the
Fig. 1 Contribution margin approach (CM = Contribution Margin, DRG = Diagnosis related groups)
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treatment of patients with this diagnosis, which must
be compensated for by the revenues from other proce-
dures. If the result is positive, no conclusions can be
drawn as to whether outcome is also positive for the
hospital because hospital-fixed costs (e.g., cost of
building maintenance) still have to be considered. The
contribution margin approach provides data on the finan-
cial outcome for a given hospital department, in our case
the orthopedic department. From its internal perspective,
the department can make economic, future-oriented deci-
sions without taking into account the hospital’s overall
fixed costs.
Objectives
We analyzed cost structures and contribution margins
for septic revision THA procedures performed in two
sessions. With this approach, the actual cost associated
with a procedure can be calculated, and the orthopedic
department performing the procedure can estimate
whether the reimbursement for this treatment covers its
cost. In addition, we present a detailed analysis of all
steps involved in septic revision THA and the corre-
sponding cost separately for the explantation and the
implantation procedure. We consider this separate cal-
culation important since, to the best of our knowledge,
this has not been done by investigators before. In
agreement with most of the published literature, we
hypothesize that the relevant variable and fixed case
costs associated with septic revision THA are not cov-
ered by current reimbursement, resulting in a loss to
the hospital [7, 13, 18].
Methods
Setting
The analysis was performed using data from a university-
affiliated hospital in central Europe providing maximum
care. In 2012, 36,345 patients were treated in the entire
hospital, which provides 926 beds in 21 departments. In
2012, the Clinic and Outpatient Clinic for Orthopedics
and Orthopedic Surgery provided inpatient health care for
more than 2000 cases [19].
Inclusion and exclusion criteria for patient data
Retrospectively, all consecutive patients undergoing revi-
sion THA in two sessions for septic loosening from
January 2009 to March 2012 were included. The analysis
was based on medical and financial data provided by the
Department of Medical Controlling. We first identified
all inpatients with a supplementary diagnosis of “Septic -
infection and inflammatory reaction due to internal joint
prosthesis” (ICD-10 Code T84.5) and a positive micro-
biological test result (positive for bacteria). In a second
step, patients not treated according to OPS codes 5–821
(Re-operation, exchange or removal of an artificial hip
joint) and 5–820 (Implantation of an artificial hip joint)
were eliminated from this initially identified set. The
remaining cases were assessed by two experienced hip
surgeons who reviewed the surgeons’ reports using a list
of predefined eligibility criteria: (i) typical pain in the leg;
(ii) imaging evidence of loosening; and (iii) characteristic
laboratory and pathophysiologic parameters in blood
and biopsy specimens from the joint. This data was ob-
tained from the patient record form including clinical
and operation notes as well as lab tests.
Economic analysis
The reimbursement of healthcare providers on the basis
of diagnosis-related groups (DRGs) all over the world
means that hospitals receive a fixed payment for a pro-
cedure. The amount is calculated on the basis of the
average costs of a set of similar procedures [9]. In our
analysis, we calculated the reimbursement the hospital
received from health insurers using the DRG-associated
cost weights from the case fee catalogue as multiplica-
tors and the base value for 2013, which was €3019.9.
This amount has to cover all costs, including variable,
case-fixed and hospital fixed (=overhead) costs (see
Fig. 1). Both hospital stays (explantation and implant-
ation) are reimbursed separately, thus revenues occur
for each stay and could be compared with the corre-
sponding costs.
We performed a cost calculation using contribution
margins as described previously by Kasch et al. [14].
Costs were analyzed using the parameters listed in
Table 1. These parameters were identified and analyzed
in terms of frequency during the hospital stay of a
patient to then assign the costs they generated. Since
hospitals typically negotiate prices for materials with
suppliers, we used the hospital’s actual purchase prices
for the analysis rather than official list prices (medica-
tion, implants, expenditure materials). For calculation
of staff costs we measured individual times of involve-
ment, and calculated costs by multiplying the average
costs per minute with the times measured. If patients
were transferred to the ICU after the operation these
costs were included as well. Information on length of
ICU stay was available to the minute. The mean ortho-
pedic cost of one ICU day (24 h), we used for calcula-
tion, was €1912.3.
Variable costs included cost for implant, drugs, blood
transfusions, laboratory, radiology, expenditure material
while case-fixed costs remained to staff, physiotherapy
and ICU. Since hospitals typically negotiate prices for
materials with suppliers, we used the hospital’s actual
purchase prices for the analysis rather than official list
prices.
For the orthopedic department, the relevant parameter
of economic provision of services is the daily contribution
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margin, which is calculated by dividing average mar-
ginal contribution II by average length of hospital stay.
The smaller the daily marginal contribution, the more
difficult it becomes for the entire hospital to recover its
fixed costs. It is essential to know the contribution mar-
gin per day of individual DRGs for comparison with
other procedures in order to identifying those with the
biggest budgetary burden. Table 2 summarizes the most
important economic terms used here.
In patients undergoing revision THA in two sessions,
each of the two hospital stays (removal of the septically-
loosened prosthesis and implantation of a new pros-
thesis) is reimbursed separately and hence we also re-
gard them as two separate stays in our analysis. This is
Table 1 Performance and cost areas for the analyzed cases
Location of cost
generation
Cause of costs Unit Costs per unit [€] Cost [€]
Normal ward
Nursing staff Nursing staff time [ppr min] Costs per min Time required x cost per unit of time
Laboratory Laboratory tests [Points] Ø Point value Points x Point value
Radiology Radiological tests [Points] Ø Point value Points x Point value
Physiotherapy Physiotherapy [Points] Ø Point value Points x Point value
Medication Medication during whole stay [€] [€] Direct costs
ICU ICU treatment [min] Costs per min Time required x costs per unit of
time
Surgical costs
Orthopedics (doctor) Orthopedic surgeon time [min] Costs per min Time required x costs per unit of
time
Orthopedics (nursing) Surgical nursing staff time [min] Costs per min Time required x costs per unit of
time
Anesthesiology (doctor) Anesthesiologist time [min] Costs per min Time required x costs per unit of
time
Anesthesiology (nursing) Anesthesiological nursing staff
time
[min] Costs per min Time required x costs per unit of
time
Implant Implant [€] [€] Direct costs





Number of sterilization boxes x costs
per sterilization of one box
Blood products Blood transfusions [€] [€] Direct costs
ICU intensive care unit
Table 2 Definition of economic terms
Term Explanation Example
DRG Revenue Net Revenue for single case Cost Weight of DRG x Base rate (€3019.9)
- Variable Costs Costs assigned to a single case Expendable material, Implants, Sterilization,
Radiology, Laboratory, Blood Products, Medication
= Marginal Contribution I
- Case-Fixed Costs Costs assigned to a single hospital department Physician Surgery, Nursing Surgery, ICU, Nursing Staff
– Normal Ward, Physiotherapy
= Marginal Contribution II
- Hospital-Fixed Costs Costs assigned to the entire hospital Administrative Personal, Energy, Water, Building
Maintenance, Gardening
= Operational Result
Perspective of Hospital Department
Marginal Contribution II/day Daily contribution of single case to cover
hospital-fixed costs
Marginal Contribution II: Average stay of single case
DRG diagnosis related groups, ICU intensive care unit
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the only possible approach that allows identification of
the factors that provide a basis for well-founded eco-
nomic decisions. The two stays per patient can also be
aggregated to calculate total cost for comparison with
other procedures or published data.
Statistical analysis and ethical approval
All data are given as means with ranges. Most cost data
are not normally distributed. We tested for normal
distribution (Kolmogorow-Smirnow test), and used the
nonparametric Mann–Whitney U-test for skewed data.
Normally distributed data were assessed using the Chi2-
test and t-test, assuming statistical significance at p < .05.
All statistical tests were performed using SPSS, version
20. The local ethics committee of Ernst-Moritz-Arndt
University Greifswald approved the study (BB 010/13)
and waived written informed consent.
Results
Patient data
Our search retrieved a total of 357 patients who met the
inclusion criteria of an ICD-10 T84.5 supplementary
diagnosis. All of them were tested for infection via joint
aspiration. A positive microbiological culture was the in-
dication for the periprosthetic infection, knowing that
there are also septic joints which are culture negative.
Three-hundred-and-twenty-one cases were eliminated,
either because they did not meet the specific eligibility
criteria for the medical OPS procedures 5–821 and 5–
820 (n = 321) or they did not meet eligibility criteria in
the surgical reports (n = 6). Thirty patients were finally
included in our analysis. All of them received a complete
THA revision. Further characteristics are summarized in
Table 3.
The 30 patients included in our analysis had a mean
age of 66.1 years with women having a significantly
higher mean age than men (70.6 versus 62.8 years; p =
0.048). Most patients (63.2 %) had infection with
Staphylococcus aureus (all methicillin-sensitive). The
total duration of both hospital stays per patient taken
together ranged from 25 to 61 days with a mean of
40.2 days. The mean duration of the first hospital stay
(explantation) was 20.5 days (13–36), while that of the
second stay (implantation) was 19.8 days (10–33) (p =
0.982). In the patient records, a mean of 9.3 additional
ICD-10 codes were documented; there were no signifi-
cant differences between men and women (p = 0.819).
Economic data
Cost
Table 1 presents the cost items we analyzed separately
for explantation and implantation procedures.
The total average costs incurred by the hospital depart-
ment for each procedure were €4147.4 for explantation
and €6680.7 for implantation (p < .001). Cost items
with significant differences between explantation and
implantation were costs for the implant (p < .001),
sterilization (p < .001), normal ward nursing services
(p < .001), and medication (p < .001).
For both procedures taken together, the average cost
per patient was €10,828.1. The cost listing in Fig. 2 indi-
cates that the largest shares of cost were accounted for
by the implant (27.3 %) and salaries for staff in the nor-
mal ward (21.0 %), while salaries for the operating the-
atre were accounted for 15.4 %. The hospital stay for
explantation accounted for 38.3 % of the average total
cost, while the second hospitalization, for implantation
of the new hip endoprosthesis components, accounted
for 61.7 %.
Figure 3 presents the relevant variable cost items (im-
plant, blood products, sterilization instruments and ma-
terials, expendable materials, laboratory tests, radiologic
tests) and fixed case cost items (normal ward staff costs,
ICU, surgery staff costs, physiotherapy) for first hospital
stay (explantation), second hospital stay (implantation),
and aggregated total hospital stay. The variable costs,
which can be more easily influenced by the operating
hospital department, account for 22.0 % of the explant-
ation costs versus 58.0 % of the costs associated with the
Table 3 Baseline demographic and clinical characteristics of the
30 patients included in the analysis of septic revision THA.
Continuous data are mean (range), categorical data are counts (%)
All cases
Total 30
Left [number] (%) 18.0 (60)
Right [number] (%) 12.0 (40)
Age [years], (range) 66.1 (43–81)
Gender
Male [number] (%) 18 (60.0)
Female [number] (%) 22 (40.0)
Pathogen [number of isolations] (%)
Staphylococcus aureus (all methicillin-sensitive) 19 (63.2)
Streptococcus agalactiae (group B Streptococcus) 5 (15.8)
Coagulase-negative staphylococci 3 (10.5)
Enterococcus faecalis 3 (10.5)
Number of diagnoses (range) 9.3 (4–19)
Number of operations (range) 2.4 (2–5)
Length of stay 40.2 (25–61)
Explantation, [days], (range) 20.5 (13–36)
Implantation, [days], (range) 19.8 (10–33)
Operation time 258.4 (117–557)
Explantation [minutes], (range) 126.5 (52–404)
Implantation [minutes], (range) 131.9 (64–282)
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implantation procedure. Unlike the fixed case costs (p =
0.214), the variable case costs were significantly different
between explantation and implantation (p < .001).
Reimbursement and contribution margin
Total reimbursement was €24,201.4 per patient. Of the
30 explantations performed, 25 (83.3 %) were assigned
to DRG I03 (revision or replacement of the hip joint
with complicated diagnosis or arthrodesis or age < 16
with (I03A) or without (I03B) extremely severe compli-
cations and/or comorbidities), while 29 implantations
were assigned to this DRG (96.7 %) (I03A: n =14,
46.7 %, I03B: n = 15, 50.0 %). Thus, the data set is quite
homogenous. Compared with the mean hospital stay in
Fig. 2 Analysis of explantation and implantation costs for septic revision total hip arthroplasty
Fig. 3 Share of variable and case-fixed costs for explantation, implantation and aggregated total hospital stay of septic revision total hip arthroplasty
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Germany for I03A (26.7 days), the patients of our study
had shorter hospital stays (explantation: 22.1 days, im-
plantation: 21.9 days). However, this does not hold for
the subset of less severe I03B cases (mean hospital stay
in Germany: 17.8 days; study: explantation: 18.0 days,
implantation: 17.4 days) [20]. The average revenues
generated by the hospital were €11,922.7 for an ex-
plantation and €12,278.7 for an implantation (p = .641).
Table 4 shows contribution margins separately for
explantations and implantations and aggregated hos-
pital stays.
Both contribution margins, I (p = 0.001) and II (p =
0.004), differ significantly between explantation and
implantation. In each single case, both variable and
fixed case costs were covered by revenues. Our ana-
lysis yielded a marginal contribution II per day of
€429.3 for explantations and of €305.5 for implanta-
tions; the difference is significant (p = 0.019).
Discussion
To our knowledge, this is the first study presenting a de-
tailed analysis of the cost of septic revision THA. Unlike
previously published studies, our approach does not ex-
clusively rely on reimbursement data but instead breaks
down the costs incurred by an orthopedic department in
performing revision THA separately for explantation
and implantation.
Most investigators report overall cost of septic revi-
sion THA [10–12, 21–25], which precludes direct com-
parison with our results as we did not include the
hospital’s fixed costs. An analysis of the fixed costs of a
hospital relies on a number of assumptions, and these
costs are of limited value for decision making and plan-
ning from the individual department’s perspective. For
example, a total cost calculation based on data of the
preceding year yields accurate results only for the time
point of identical total case numbers, all other things
being equal, while costs are underestimated before and
overestimated after that date. Moreover, the hospital’s
fixed costs are more rigid and can only be influenced
on a longer-term basis. This means that they can be
neglected in an initial analysis of processes aimed at
identifying cost factors that are relevant for decision-
making from the point of view of the department pro-
viding the services.
As the clinical picture which leads to septic THA revi-
sion is dangerous and often life-threatening, decisions
are driven by medical needs rather than economic con-
siderations. Surprisingly, our analysis revealed that the
department’s total cost for a septic revision THA pro-
cedure was €10,828.1 - far below the average reimburse-
ment of €24,201.4. Thus, a considerable proportion of
the average reimbursement for septic THA revision
(55.3 %) contributes towards the hospital’s fixed costs,
which are not included in our analysis. Published data
suggest that the average fixed costs of a hospital account
for 65–75 % of its total cost [16, 17]. While our data
provide no information on whether the entire hospital
makes a profit or loss, they show that the orthopedic de-
partment makes no deficit when performing septic revi-
sion THA. The largest shares of the variable case costs
are accounted for by staff (36.4 %) and the implant
(27.3 %). Due to the costs of the implant, which occur
only in second hospital stay variable costs are significant
higher for the implantation stay.
Never the less in a hospital all clinical departments
are co-responsible of the economic viability. So it is
also required to have a global perspective to assure the
economic sustainability of the whole hospital. Managers
and clinical leaders must cooperate this in line. Positive
contribution margins I and II are important but not
enough, as also contribution margin III and IV needs to
be positive to achieve a positive over all result.
While DRG-based reimbursement (€11,922.7 for ex-
plantation vs. €12,278.7 for implantation) and hospi-
talization duration (20.5 days for explantation vs.
19.8 days for implantation) are nearly identical for the
two procedures, the department’s costs related to
Table 4 Marginal contributions of septic explantations and implantations [€] (range)
Explantation (n = 30) Implantation (n = 30) Complete casea (n = 30)
Cost 4147.4 (1941–12,192.3) 6680.7 (3932.8–13,661.8) 10,828.1 (5083.6–21,875.7)
DRG Revenue 11,922.7 (6797.8–14,610.3) 12,278.7 (9817.7–16,552.1) 24,201.4 (16,615.5–31,162.4)
- Variable Costs 910.6 (253.6–4741.5) 3876.3 (1583.1–8568.0) 4786.9 (2176.8–13,309.5)
= Marginal Contribution I 11,012.1 (6478.8–14,244.6) 8402.4 (4393.5–13,027.2) 19,414.4 (13,472.8–25,746.0)
- Case-Fixed Costs 3236.8 (1583.2–9083.9) 2804.4 (1005.8–6726.1) 6041.2 (2589.1–13,773.2)
= Marginal Contribution II 7775.3 (2418.0–12,622.4) 5598.0 (948.5–10,534.5) 13,773.3 (5348.5–2,3156.9)
Marginal Contribution I/day 586.8 (282.0–1092.74) 451.0 (191.0–1091.8) 500.8 (284.1–1029.8)
Marginal Contribution II/day 429.3 (69.1–971.0) 305.5 (43.1–877.9) 353.2 (131.2–926.3)
aComplete case is the aggregate of the two separate hospital stays for explantation and implantation
DRG diagnosis related groups
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implantation are much higher than for explantation (dif-
ference of €2533.3). This difference is mainly attributable
to implant prices, which account for a large proportion of
the total cost. Hence, we may conclude that cost savings
can be realized by negotiating better purchase prices
with suppliers. As patients in need of septic revision
THA have an above-average morbidity and need more
nursing and physician care at the time of explantation
surgery, staff costs on the normal ward also differ sig-
nificantly between explantation and implantation des-
pite similar hospitalization durations (€1361.6 vs.
€909.4, p < 0.001). It should be pointed out here ser-
iously that, while cutting cost may be essential for the
economic survival of many hospitals patient safety and
good outcome must always come first. Economic and
medical management must work to together to find
payable but medically acceptable solutions.
Comparison of daily contribution margins allows us
to compare how much individual DRGs can contribute
to the payment of a hospital’s fixed costs. In the case
analyzed here, contribution margins per day show that
the explantation procedure results in a higher financial
benefit for the orthopedic department than the im-
plantation procedure (€429.3 versus €305.5). Although
patients are very sick at the time of explantation, the
higher contribution margin might be attributable to the
fact that no implant costs are involved during the first
stage of septic THA revision. With regard to previously
published data septic implantations seem to be compar-
able to aseptic THA revisions (€298.2) in terms of con-
tribution margins [26]. This is very surprising because
septic procedures are more difficult and complex. Over-
all, our analysis shows that both explantation and im-
plantation have a large share in paying the fixed costs
of a hospital.
Limitations
Our study has some limitations, which must be taken
into account when interpreting our results. The retro-
spective nature has the usual advantages and disadvan-
tages of this design in terms of data quality, number of
patients included, and representativeness. The total
number of cases analyzed is not large, but this ensures
that consistent data were available for all patients in-
cluded. Due to technical aspects it was not possible to
calculate costs for staff from other medical disciplines,
e.g., during councils, thus the real costs for the hos-
pital stay are slightly underestimated. As we present
data from Germany, the results has to be interpreted
and compared with regard to the diverging international
health care systems and economic circumstances. Never-
theless our approach to calculate contribution margins is
transferable. Compared with published data, the operation
time and length of hospital stays appear rather short in
our patients, which might suggest that the patients of our
study population were in less serious conditions and
thus could be treated at lower costs. Comparison with
future studies will show whether our population is
representative.
Conclusions
Our analysis for the first time provides orthopedic sur-
geons with data on those parts of hospital costs they can
influence. It might also assist hospitals in scenario plan-
ning with regard to the overall economic context. In
summary, our cost analysis of septic revision THA pro-
cedures in two sessions indicates that more than half of
the per-case reimbursement (55.3 %) is available for cov-
ering the hospital’s fixed costs. Hence, our hypothesis
that hospital departments incur an unreimbursed loss
when performing septic revision THA has been refuted.
None of the 30 cases included in our analysis produced
a loss for the orthopedic department. Our detailed ana-
lysis of explantation and implantation procedures for
the first time shows that variable costs account for a
large proportion of the costs associated with implant-
ation procedures and might be a promising target for
cost-saving measures. Purchase prices for hip implants
and staff cost have been revealed as major cost factors
that the hospital might influence.
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